|
WO2010008244A2
|
|
Pharmaceutical preparation
|
|
KR20100008356A
|
|
Pharmaceutical formulation comprising channel blockers
|
|
WO2009151295A2
|
|
Pharmaceutical formulation comprising azelnidipine and hmg-coa reductase inhibitor or angiotensin ii receptor blocker
|
|
CN102186879A
|
|
Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
|
|
WO2009142421A2
|
|
Pharmaceutical preparation (pharmaceutical formulation)
|
|
ZA200903204B
|
|
Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory
|
|
KR20090114332A
|
|
Pharmaceutical formulation
|
|
WO2009134053A2
|
|
Pharmaceutical composition containing thiazide-based compound with controlled release and angiotensin-ii-receptor blocker
|
|
WO2009125987A2
|
|
Pharmaceutical formulation
|
|
CN102014881A
|
|
Pharmaceutical preparation
|
|
KR20090091085A
|
|
Controlled-release pharmaceutical formulation
|
|
WO2009104916A2
|
|
Pharmaceutical formulations for the treatment of cardiovascular diseases
|
|
CN101951896A
|
|
Composite preparation
|
|
WO2009088220A3
|
|
N,n-dimethyl imidodicarbonimidic diamide nicotinate, method for producing the same and pharmaceutical composition comprising the same
|
|
CN101932322A
|
|
Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid
|
|
WO2009038396A2
|
|
N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
|
|
CN101796035A
|
|
1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same
|
|
KR20090114190A
|
|
Controlled release complex composition comprising hmg-coa reductase inhibitors and angiotensin-ii-receptor blockers
|
|
KR20090114122A
|
|
Controlled release pharmaceutical composition containing angiotensin-ii-receptor blockers and thiazides
|
|
US2008241240A1
|
|
Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
|
